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Background
The phase III prime-boost trial of ALVAC-HIV®
(vCP1521) and AIDSVAX® B/E spanned 2003 to 2009 in
Thailand. Both candidates express HIV CRF 01_AE and
subtype B antigens, the predominant circulating HIV-1
subtypes in Thailand. This preliminary study assessed cell-
mediated immune (CMI) responses, viral load and CD4
counts in a subset (N=47) of anti-retroviral naïve incident
infections (< 270 days after estimated infection) that
occurred during the trial.
Methods
Study participants were randomized 1:1, vaccine:placebo.
The immunization regimen was 0, 1, 3 and 6 months for
ALVAC-HIV®, with AIDSVAX® being administered at 3
and 6 months. Cytotoxic T lymphocyte (CTL) assays were
conducted on freshly isolated peripheral blood mononu-
clear cells (PBMC) in a standard chromium release assay
using autologous EBV-transformed B cells as targets
(N=47). Interferon-gamma (IFN-γ) ELISpot assays were
performed using cryopreserved PBMC (N=43). Target
antigens for both CMI assays matched those of the vaccine
candidates. Concurrent viral load and CD4 counts were
measured using commercial assays. HIV genotyping was
performed using the multiregion hybridization assay. 
Results
Data are still blinded with respect to immunization status.
The median time from infection to CMI assessment was
164 days (range: 113-265).  The frequency of HIV-specific
CD8+ CTL activity was 64%, with equivalent responses to
Env (19/47) and Gag/Pol (18/47) antigens.  HIV-specific
IFN-γ ELISpot responses were measured in 47% of sub-
jects, but the response was predominantly to Gag – 37%
versus 19% for Env. Median viral load and CD4 counts
were 25338 copies/ml (range: <50-272509) and 571
cells/µl (range: 220-1067), respectively. CRF01_AE was
the predominant infecting subtype (82%; 37/45).
Conclusion
Robust CD8+ mediated CTL responses to HIV antigens
expressed by the ALVAC-HIV® immunogen were observed
in participants who became infected during the trial.
Determining the relevance of these responses to viral con-
trol and/or CD4 T cell counts following un-blinding
(October, 2009) constitutes a high priority.
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